Showing results (571-580 of 583) with videos related to

Sort By:
Pageof 59
British Journal of Anaesthesia|June 28, 2023
German Patient Blood Management Network: effectiveness and safety analysis in 1.2 million patientsPatrick Meybohm, Elke Schmitt, Suma Choorapoikayil, et al.
Journal of Cellular Biochemistry. Supplement|January 1, 1996
Strategy and planning for chemopreventive drug development: clinical development plans IIG J Kelloff, J A Crowell, E T Hawk, et al.
Ebiomedicine|February 28, 2025
Early, very high-titre convalescent plasma therapy in clinically vulnerable individuals with mild COVID-19: an international, randomised, open-label trialSimone Hoffmann, Eva Schrezenmeier, Maxime Desmarets, et al.
Bone Marrow Transplantation|January 31, 2018
Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM)Peter Bader, Zyrafete Kuçi, Shahrzad Bakhtiar, et al.
Vox Sanguinis|September 30, 2017
Enlargement of the WHO international repository for platelet transfusion-relevant bacteria reference strainsE Spindler-Raffel, R J Benjamin, C P McDonald, et al.
Ebiomedicine|September 17, 2020
Modulating endothelial adhesion and migration impacts stem cell therapies efficacyRichard Schäfer, Matthias Schwab, Georg Siegel, et al.
Trials|February 6, 2019
Liberal transfusion strategy to prevent mortality and anaemia-associated, ischaemic events in elderly non-cardiac surgical patients - the study design of the LIBERAL-TrialPatrick Meybohm, Simone Lindau, Sascha Treskatsch, et al.
Ebiomedicine|September 13, 2020
Cell motility and migration as determinants of stem cell efficacyLusine Danielyan, Matthias Schwab, Georg Siegel, et al.
Cells|December 11, 2019
Children and Adults with Refractory Acute Graft-versus-Host Disease Respond to Treatment with the Mesenchymal Stromal Cell Preparation "MSC-FFM"-Outcome Report of 92 PatientsHalvard Bonig, Zyrafete Kuçi, Selim Kuçi, et al.
The Journal of Clinical Investigation|November 3, 2022
One-year follow-up of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patientsSixten Körper, Beate Grüner, Daniel Zickler, et al.
Pageof 59